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Abstract 
Berberine, an isoquinoline alkaloid, is an active component from a Chinese medicinal 
herb Coptis chinensis Franch. It is extensively used in traditional Chinese 
prescriptions. Recent studies demonstrated that berberine exerted anti-cancer 
activities. However, details of its biologic activity are lacking. 
To understand the pharmacological actions of berberine, two hepatocarcinoma cell 
lines, Huh7 and JHH4, and normal liver cell line WRL68 were used in this study. The 
results indicate that berberine significantly reduced cell viabilities in hepatocarcinoma 
cell lines, while it exerted minimal inhibitory effect in normal liver cells. 
The experimental findings show that apoptotic effects of berberine in 
hepatocarcinoma cell lines were due to its ability to activate caspases. Caspase 
activation led to a decrease in the protein expression of full-length Bid in cytosol, 
where it was likely to be truncated and translocated to mitochondria, resulting in 
apoptosis. Furthermore, the results indicate that berberine triggered Gi/S cell cycle 
arrest in a dose-dependent manner. The present study provides experimental 
evidences that berberine possess anti-cancer activities in human hepatocellular 
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Chapter 1 Introduction 
1.1 Hepatocellular carcinoma 
1.1.1 Overview 
Liver cancer is the fifth most popular cancer worldwide and the second leading cause 
of cancer death in men (Jemal et al , 2011). In women, it is the seventh most 
frequently diagnosed cancer and the sixth most common cause of cancer death. 
There were 694,000 deaths from liver cancer in 2008 (Ferlay et al” 2010). The overall 
ratio of mortality to incidence for liver cancer was 0.93. Due to its high fatality, liver 
cancer is the third most common causes of death from cancer worldwide (Ferlay et al., 
2010). Occurrence rate of liver cancer in males was twice as high as in females 
worldwide. Among primary liver cancers occurring worldwide, hepatocellular 
carcinoma (HCC) represents the major histological type, which accounts for 70% to 
85% of cases (Perz, Armstrong, Farrington, Hutin, & Bell, 2006). 
Half of the liver cancer cases and deaths were estimated to occur in China for both 
men and women in 2008 (Ferlay et al., 2010). The high HCC rates in China, other 
parts of Asia, and sub-Saharan Africa largely reflect the elevated prevalence of 
chronic hepatitis B virus (HBV) infection, with over 8% of the populations in these 
regions chronically infected with the virus (Schottenfeld, Fraumeni, Colditz, Samet，& 
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Whittemore, 2006). HBV infection accounts for about 60% of total liver cancer in 
developing countries and for about 23% of cases in developed countries (Parkin, 
2006). Hepatitis C virus (HCV) infection accounts for 33% of total liver cancer in 
developing countries, and for 20% in developed countries. Interaction of aflatoxin B 
(AFB) exposure with chronic HBV infection is known to increase liver cancer (Ming 
et al., 2002; Parkin, 2006). However, the contribution of aflatoxin B1 (AFBl) 
exposure to liver cancer cases in parts of Asia, where the exposure is prevalent, is not 
yet known (International Agency for Research on Cancer [IARC], 2002). 
In the United States and other low-risk Western countries, alcohol-associated cirrhosis 
and possibly non-alcoholic fatty liver disease related to obesity, are thought to be the 
leading causes of liver cancer (El-Serag, 2007). 
Liver cancer incidences are ascending in the United States and Central Europe. 
Possible leading causes are obesity epidemic and the increase in HCV infection 
through continued transmission by injection drug users (Altekruse, McGlynn, & 
Reichman, 2009; Bosetti et al., 2008; El-Serag, 2007). Contrary to the trend in the 
low-risk areas, possibly due to the HBV vaccine, incidence rates of liver cancer in 
some historically high-risk areas decreased (Bosetti et al., 2008). In Taiwan, the 
universal infant hepatitis vaccination programs reduced liver cancer incidences by 
nearly two-thirds in children and young adults (Chang et al., 2009). 
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As of 2009, a total of 177 countries (91%) had introduced the HBV vaccine into their 
national infant immunization schedules (World Health Organization [WHO], 2011). 
No vaccine is available for HCV. Preventive strategies against HCV include screening 
of donor's blood for antibodies to HCV, instituting adequate infection control practices 
during medical procedures including the use of oral delivery medicines where 
possible, and needle exchange programs among injection drug users (Jemal et al, 
2011). Crop substitution and improved grain storage practices have been shown to 
reduce AFB contamination in sub-Saharan Africa (Turner et al., 2005). 
1.1.2 Risk factors 
HBV or HCV infection, alcohol consumption, and diabetes mellitus alone were found 
to be significant risk factors for HCC development in a recent study in the United 
States (Hassan et al., 2002). The study also reported that synergy existed between 
alcohol consumption and chronic HBV or HCV infection and diabetes mellitus. 
Moreover, exposure to chemicals such as AF is also an independent risk factor for 
HCC development. In addition, androgens have been known to be associated with an 
increased incidence of liver neoplasm, and their hepatic effect is receptor-mediated. 
However, the pathogenesis of HCC is still poorly understood. 
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HBV and HCV infection 
Chronic HBV infection is the most prevalent cause of HCC worldwide. HBV 
infection accounts for 60% of total liver cancer in developing countries, and for about 
23% of cases in developed countries (Parkin, 2006). HCV infection accounts for 33% 
of total liver cancer in developing countries, and for 20% in developed countries. 
Epidemiologic studies have established a close association between HCC occurrence 
and chronic HBV infection (Kew & Popper, 1984). A recent study reported that 
chronic HBV and HCV infection increased the risk of HCC approximately 13-fold 
and 15-fold respectively (Hassan et al., 2002). In addition, the presence of cirrhosis 
seems to play a central role in both HBV and HCV, as generally 60% to 80% of HCC 
cases are associated with the disease (Bosch & Munoz, 1991). Another recent study 
found that 69% of HCV-infected HCC patients and 35% of HBV-infected HCC 
patients had cirrhosis (Hassan et al., 2002). Even though some HBV- or HCV-infected 
HCC patients did not develop cirrhosis, a direct carcinogenic role has been suggested 
for HBV and HCV. Integration of the HBV genome into cellular DNA was found in 
most HBV-induced HCC patients (Kew, 1996). The HCV core protein was implicated 
to have a direct carcinogenic role in HCC development (Moriya et al” 1998; Ray, 
Meyer, & Ray, 1996). Both viruses may directly induce HCC by contributing to 
histopathologic changes in the liver (Hassan et al., 2002). 
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In fact, HBV virus may be the primary carcinogen in nearly 80% of HCC patients 
worldwide (Oberfield, Steele, Gollan, & Sherman, 1989). A prospective study in 
Taiwan showed that the relative risk of HCC developing in a chronic HBV carrier was 
more than 200, with a lifetime risk in humans of approximately 50% (Beasley & 
Hwang, 1984). The mechanism by which chronic HBV infection leads to liver cancer 
remains unclear, but apparently it is related to the integration of hepatitis B viral DNA 
into the host genome (Dejean, Bougueleret, Grzeschik, & Tiollais, 1986). 
Cirrhosis 
Between 30-70% of HCC patients also have cirrhosis. The risk of liver cancer 
development varies according to the type of cirrhosis present (Melia, Wilkinson, 
Portmann, Johnson, & Williams, 1984). Primary liver cancers will eventually develop 
in 2-3% of patients with alcoholic cirrhosis, compared with 10% of patients with the 
macronodular, posthepatic form of cirrhosis (Oberfield et al, 1989). The risk of HCC 
development is about 40 times greater in patients with cirrhosis than individuals 
whose liver functions normally. The risk is higher in men than in women with 
cirrhosis, with the male-to-female ratio of about 2:1. Cirrhosis associated with 
a,-antitrypsin deficiency and other inborn errors of metabolism, for example, 
tyrosinemia, leads to an increased incidence of HCC (Oberfield et al., 1989). Rare 
cases were reported for patients with HCC complicating Wilson's disease (Cheng, 
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Govindarajan, & Redeker，1992). Liver cancer in patients with cirrhosis associated 
with Wilson's disease was relatively absent (Oberfield et al , 1989). However, HCC 
occurs in 10-22% of cirrhotic patients with hemochromatosis (Oberfield et.al, 1989). 
Exposure to chemicals 
Aflatoxin 
AFs are carcinogenic in several animal species but their potency varies, among which 
AFBl is the most potent hepatotoxin (C. Chen & D. Chen, 2002). AFBl is a human 
hepatocarcinogen, and is also a liver carcinogen when fed to rodents (Wogan & 
Newberne, 1967; Wogan, 1992). AFBl is the secondary metabolite produced by 
Aspergillus flavus and Aspergillus parasiticus, which grow in tropical and subtropical 
regions of the world. AFBl contaminates foods such as com, rice and peanuts which 
are stored under tropical conditions (Wogan, 1976). AFBl metabolism produces the 
active form of AFBl, AFB 1-8, 9-epoxide, which is highly mutagenic and 
carcinogenic for the liver in rats and other experimental animals, with mutagenicity 
correlating with carcinogenicity (Newberne & Wogan, 1968; Swenson, E. Miller, & J. 
Miller, 1974). AFBl is implicated by epidemiological studies as a causative factor for 
HCC in humans (Ross et al., 1992). The clinical appearance of HCC is the result of a 
series of changes at cellular and molecular level. Evidences have shown that DNA 
damage by environmental chemical carcinogens is critical in this process (Zhang, 
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2010). 
AFBl forms AFBl-DNA adducts by covalently binding to guanine and cytosine 
residues of DNA both in vivo and in vitro (Croy, Essigmann, Reinhold, & Wogan, 
1978; Yu, Bender, & Hutchcroft, 1994). It also forms RNA and protein adducts, which 
impairs DNA, RNA and ultimately protein synthesis (Santella, Chen, Zhang, Yu, & 
Wang, 1998; Meneghini & Schumacher, 1977; Amstad & Cemtti, 1983). AFBl-DNA 
adducts were detected using immunohistochemical assay in smeared HCC tissues and 
HCC sections (Chen, Zhang, Lu, & Santella, 1992; Zhang et al., 1991; Lunn et al.; 
1997). The presence of AFBl-DNA adducts can lead to genetic alternations in loci 
involved in HCC development (Zhang, 2010). The recent epidemiologic studies 
suggested an additive effect of AFBl and HBV infection on HCC risk (Wu et al., 
2007). The highly aberrant patterns of genetic alternations detected in different areas 
suggested that AFBl has genotoxic effects (Zhang, 2010). HBV infection and high 
AFBl exposure may have combined effects which could promote HCC development 
(Lunn et al., 1997; Wong et al., 2000). 
Molecular mechanisms underlying the carcinogenic effects of AFBl have been 
investigated in rodents. HCC induced by AFBl in Fischer 344 rats showed activating 
mutations in codon 12 of K-ras (McMaho, Davis, Huber, Kim, & Wogan, 1990). 
However, the incidence of point mutation of K-ras and N-ras oncogenes in human 
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HCC was low (Tsuda et al., 1989). AFBl interfered with cell cycle regulation in an in 
vitro study (Ricordy, Gensabella, Cacci, & Augusti-Tocco, 2002). AFBl also induced 
mitotic recombination (Stettler & Sengstag, 2001), and minisatellite rearrangements 
(Kaplanski, Chisari, & Wild, 1997). Therefore, AFBl may contribute to genetic 
alternations in HCC by alternative mechanisms, which are mitotic recombination and 
genetic instability (Wild & Turner, 2002). 
Vinyl chloride 
Vinyl chloride (VC) is a major industrial chemical, a wide-spread environmental 
contaminant, and a known animal and human carcinogen (lARC, 1974). VC is a 
colorless toxic gas extensively used in the plastic industry. VC is absorbed after 
respiratory exposure, and is activated primarily in hepatocytes by the enzyme 
cytochrome P450 (CYP2E1) (Zhang, 2010). Metabolites of VC can react with DNA 
bases to form DNA adducts (Guengerich, 1992). VC induces several DNA adducts 
after metabolic activation, and different studies have shown that these DNA adducts 
are responsible for specific mutations (Barbin et al., 1997). Barbin et al. (1997) also 
suggested that VC is a multi-potential carcinogen in animals. The p53 mutation 
pattern in HCC in workers exposed to VC included point mutations in codons 175, 
245, 248, 273 and 282, however, it remains unclear whether these genetic alternations 
were directly associated with VC exposure (Weihrauch, Lehnert, Kockerling, 
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Wittekind, & Tannapfel, 2000). No direct evidence has shown that genetic 
polymorphisms of metabolizing enzymes are correlated with HCC development due 
to VC exposure (Zhang, 2010). 
Poly cyclic aromatic hydrocarbons 
Cigarette smoking is associated with a significantly increased HCC risk in some Asian 
countries (Chen et al., 1996; Tu, Gao, Zhang, & Gu, 1985; Goodman et al., 1995). 
Tobacco smoke consists of chemical carcinogens, such as polycyclic aromatic 
hydrocarbons (PAHs) and aromatic amines. Benzo[a]pyrene (BP) and N-nitrosamines 
are examples of PAHs which can be found in Tobacco smoke. PAHs are produced 
during combustion of all organic materials, and are ubiquitous in the environment. 
Therefore, PAHs are also found in polluted air, smoked and charbroiled foods, 
contaminating fats and grains (Phillips, 1999). PAHs, especially BP, are known animal 
and human carcinogens (lARC, 1983). 
PAH-DNA adducts were detected in HCC tissue samples in human (Chen et al., 2002; 
Zhang et al., 2006). Levels of PAH-DNA adducts in liver tissues and the combination 
of their levels with some susceptibility factors including HBV infection and AFBl 
exposure, were found to be in association with HCC (Chen et al., 2002). A recent 
study reported that PAH-albumin adducts were associated with increased HCC risk, 
especially among those with high exposure to AFBl, and environmental PAH 
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exposure may enhance the hepatic carcinogenic potential of HBV infection (Chen et 
al., 2002). 
Alcohol consumption 
Alcohol consumption is an independent risk factor for HCC. Ethanol is a hepatotoxin. 
It is an important chemical solvent and promotes the absorption of ingested toxins 
(Chen, Yu, & Liaw, 1997). Alcohol consumption is the common cause of cirrhosis, a 
primary clinical predictor of HCC, in the US and European countries. HCC 
development is correlated with the magnitude of alcohol consumption (Austin et al., 
1986; Tagger et al., 1999; Hassan et al., 2002). Previous studies have suggested that 
heavy alcohol consumption could induce direct hepatic cellular injury and toxicity, 
which could lead to liver fibrosis and cirrhosis (Batey, Burns, Benson, & Byth, 1992). 
Moreover, microsomal enzymes in liver, which oxidize and metabolize ethanol, may 
increase conversion of procarcinogens to carcinogens (Lieber, Seitz, Garro, & Womer, 
1979). 
Ethanol damages liver by oxidative stress. Alcoholic hepatitis shows increased levels 
of isoprostanes, which are markers of oxidative damage (McClain et al., 2002). 
Acetaldehyde and oxygen-free radicals are generated during ethanol metabolism, 
which are highly associated with the development of alcohol-related liver diseases 
through oxidative stress (Lieber, 1990). Oxidative stress may induce liver cell damage 
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directly by initiating peroxidation of membrane lipids. Moreover, oxidative stress may 
lead to the accumulation of oncogenic mutations (Zhang, 2010). Oxidative damage 
may also accelerate telomere shortening, which correlates with the development of 
liver cirrhosis, chromosomal instability and HCC (Kurz et al., 2004). 
However, the mechanism through which heavy alcohol consumption promotes the 
development of HCC is not well known (Hassan et al., 2002). 
Diabetes m el I it us 
Studies have shown that diabetes mellitus is significantly related to the risk of HCC 
development (Yu, Tong, Govindarajan, & Henderson，1991; La Vecchia, Negri, 
Decarli, & Franceschi, 1997; Lagiou et al., 2000; Hassan et al., 2002). Diabetes 
mellitus promotes the development of HCC through an unknown mechanism. 
However, previous studies suggested oxidative stress was associated with the 
pathogenesis and complications of diabetes mellitus as a result of hyperglycemia 
(Rosen et al., 2001; Kar & Chakraborti, 1999; Ford & Cogswell, 1999; Oberley, 1988; 
Gillery, Monboisse, Maquart, & Borel, 1989). An increased blood glucose level in 
diabetes mellitus patients may stimulate glycosylation of proteins, which include 
hemoglobin, leading to an increase in the release of iron from hemoglobin, and further 
production of free radicals, which cause oxidative stress (Kar & Chakraborti, 1999; 
Ford & Cogswell, 1999). An early study reported a high concentration of serum 
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ferritin in diabetes mellitus patients, which reflected increased body iron stores in 
patients (Ford & Cogswell, 1999). Hassan et al. (2002) suggested that iron is a 
powerful pro-oxidant and oxidative stress is increased in impaired glucose tolerance 
states. Alcohol-induced oxidative stress may increase the susceptibility of patients 
having diabetes mellitus to cirrhosis, DNA damage, and HCC development (Hassan et 
al., 2002). Alcohol-induced oxidative stress may also increase the susceptibility of 
diabetes mellitus development (Hassan et al., 2002), which may explain early onset of 
diabetes is related to HCC development (Yu et al., 1991; La Vecchia et al., 1997). 
1.1.3 Treatment of HCC 
Phases of HCC 
The natural history of HCC can be divided into three distinct phases, which are 
molecular phase, preclinical phase, and clinical phase (Trevisani, Cantarini, Wands, & 
Bemardi, 2008). The molecular phase includes the sequential genomic alternations 
leading to cell transformation (Trevisani et al., 2008). The preclinical phase covers an 
initial period, in which the tumor is too small to be detected by imaging techniques 
(Trevisani et al., 2008). The second period in preclinical phase is the diagnostic phase, 
during which the tumor is detectable but is still asymptomatic (Trevisani et al., 2008). 
Finally, the clinical phase starts with the occurrence of symptoms caused by the tumor 
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burdens (Trevisani et al., 2008). HCC usually becomes symptomatic when it reaches 
4.5-8 cm in patients suffered from chronic liver disease (Trevisani et al., 2008). 
Treatment options 
Screening for primary liver cancer is difficult because the tumor seldom gives rise to 
early symptoms (Oberfield et al., 1989). Current treatment options are limited and 
does not provide effective cure for HCC. 
Surgery 
The criteria for liver resection are stringent. Patients should have good liver fiinction, 
and they should not have obvious metastasis. These patients need surgical exploration 
to determine the location, extent and the resectability of the tumor (Oberfield et al., 
1989). However, only a minority of these patients will be suitable for surgical 
excision due to other limitations. For example, if a patient suffers from cirrhosis, he or 
she will not be able to undergo liver resection, since cirrhosis impacts the regeneration 
of liver. Oberfield et al. (1989) suggested the criteria for resectability of a HCC are a 
solitary lesion limited to one lobe of the liver, and absence of cirrhosis, jaundice, or 
ascites. Surgical therapy offers the greatest likelihood of cure with a 10-year actual 
disease-specific survival rate of 17-25% at present (Tomlinson et al., 2007; Fong, 
Fortner, Sun, Brennan, & Blumgart, 1999). Despite complete resection, more than 
75% of patients develop recurrence (Govindarajan et al., 2011). Achieving a complete 
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surgical resection is often technically difficult and sometimes impossible. 
Radiotherapy 
Radiotherapy is believed not very useful for HCC patients because normal liver 
tolerance is restricted to 2,500 to 3,000 cGy (Oberfield et al., 1989). Moreover, 
conventional photon radiotherapy for HCC may induce risk of hepatic toxicity 
(Komatsu et al., 2010). 
Chemotherapy 
Combination chemotherapy using 5-fluorouracil, cisplatin, and mitoxantrone (FMP) 
could achieve a response rate of more than 20% in HCC patients, however, the 
beneficial effect was compromised by formidable side effects (Yeh et al., 2011). 
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1.2 Berberine - a compound derived from Traditional 
Chinese Medicine 
1.2.1 Traditional Chinese Medicine 
Conventional HCC therapies include surgery, chemotherapy and radiotherapy, as 
discussed above. However, these therapies have limitations and negative impacts. 
First, most cancer cases are diagnosed at the late stage of development and patients 
are unable to undergo surgery. Second, the recurrence of cancer is common in patients 
who have had a resection, while the post-operative survival rate for most cancers is 
less than 5 years. Third, malicious side effects are observed for chemotherapy and 
radiotherapy against cancer (National Cancer Institute, 2008). For cancers which are 
relatively resistant to chemotherapy or radiotherapy, these treatments only have 
minimal effect at improving patients' survival (Qi et al., 2010). Despite the 
unsatisfactory treatment outcome of current therapies, the use of complementary and 
alternative medicine (CAM) has become more popular among cancer patients in 
Western countries, with a prevalence of 80% (Xu, Towers, Li, & Collet, 2006; Cui, 
Wang, Kokudo, Fang, & Tang, 2010). Traditional Chinese Medicine (TCM) has been 
used in China, Japan, and other Asian countries for hundreds of years. These 
medicines are widely accepted as current forms of CAM in cancer treatment in the 
United States and Europe (Wong, C.Sagar，& S.Sagar, 2001; Gai et al., 2008). 
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1.2.2 Berberine 
Berberine is an isoquinoline alkaloid from the Chinese medicinal herb Coptis 
chinensis. It is found in the roots, rhizome and stem bark of other important medicinal 
plants, such as Berberis vulgaris (barberry), Berberis aquifolium (Oregon grape), and 
Berberis aristata (tree turmeric) (Singh, Vaid, Katiyar, Sharma, & Katiyar, 2011). 
Berberine is extensively used in traditional Chinese prescriptions due to its 
anti-protozoal, anti-hypertensive (Bova, Padrini, Goldman, Berman, & Cargnelli, 
1992), anti-bacterial (Amin, Subbaiah, & Abbasi, 1969), anti-inflammation (Akhter, 
Sabir, & Bhide, 1977), anti-cholinergic (Tsai & Ochillo, 1991), and anti-arrhythmic 
properties (Wang & Zheng, 1997). Previous studies reported that berberine inhibited 
COX-2 transcriptional activity in human colon cancer cells (Lin et al., 1999; Fukuda 
et al., 1999b). Berberine inhibited inflammation in human hepatoma cells (Fukuda et 
al., 1999a), however, details of its biologic activity are lacking. 
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Figure 1 Structure of berberine 
Berberine has a molecular formula of CzoHisNO/, and the molar mass of 336.361 g/mol. 
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1.3 Cell cycle 
1.3.1 An Overview of cell cycle 
The eukaryotic cell cycle comprises four phases in proliferating cells: Gap phase 1 
(Gi); DNA synthesis phase (S); Gap phase 2 (G2 ) , and mitosis phase (M). The 
transition which occurs at the restriction point (R) in Gi commits the cell to the 
proliferative cycle. If conditions which signal this transition are absent, the cell exits 
the cell cycle and enters Go , a resting phase when the cell has stopped dividing 
(Cooper & Hausman, 2009). G2 is the phase when the cell prepares for division. M 
phase consists of prophase, metaphase, anaphase, and telophase. The chromosomes 
separate while the cell divides during M phase. 
1.3.2 Cell cycle and carcinogenesis 
Dysregulation of the cell cycle is one of the hallmarks of carcinogenesis (Schwartz & 
Shah, 2005). Cell cycle protects the cell from DNA damage, while the cell cycle arrest 
is a survival mechanism in which the tumor cell can repair damaged DNA (Schwartz 
& Shah, 2005). Cell cycle is controlled at different checkpoints. When cells suffer 
extracellular or intracellular stress or both, the cell cycle checkpoints, especially Gi/S 
and G2/M checkpoints, are activated (Wang et al” 2009). Checkpoints are a regulatory 
mechanism which ensures genomic integrity and prevents the propagation of 
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transformed cells (Hartwell & Kastan, 1994). Gi arrest prevents aberrant replication 
of damaged DNA, while G2 arrest allows cells to avoid segregation of defective 
chromosomes (Arima et al., 2004). Leading causes of defective cell cycle checkpoints 
include gene mutations, chromosome damage, and aneuploidy, and these defects may 
lead to tumor formation (Hartwell & Kastan, 1994; Paulovich et al., 1997). 
Gi arrest after DNA damage is primarily induced by stabilization of the p53 tumor 
suppressor protein (Lakin & Jackson, 1999). Responsive to DNA damage, p53 is 
activated and post-translationally modified (Arima et al., 2004). p53 is able to serve as 
a transcription factor which binds DNA sequence-specifically in response to cellular 
stress, and triggers the expression of genes which contain a p53 binding-site element 
in their promoter or introns (Bourdon et al. 1997 ； El-Deiry et al., 1992 ； Funk et al, 
1992). The cdk inhibitor was known to be a p53-responsive gene, which 
is an important player in p53-induced Gi arrest (Arima et al., 2004). The inhibitory 
activities of do not attribute only to inhibition of cdk activity, but also 
other cellular activities, such as interaction with proliferating cell nuclear antigen 
(PCNA) to inhibit DNA replication (Chen, Smith, O'Connor, & Fomace, 1995; Luo, 
Hurwitz, & Massague, 1995; Sherr & Roberts, 1995; Waga, Harmon, Beach, & 
Stillman, 1994). Thus, studies of the cell cycle may yield useful information on how 
cancer cells are regulated at the cellular level. 
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1.4 Molecular mechanism of apoptosis 
1.4.1 Overview of apoptosis 
The term apoptosis was proposed by Kerr, Wyllie, and Currie in 1972. Apoptosis 
describes a morphology which is a distinctive type of cell death, and is associated 
with normal physiology (Henkart, 1999). Apoptosis, or programmed cell death, is 
different from necrosis, which happens when cells are acutely injured (Henkart, 1999). 
Apoptosis occurs when nuclear chromatin condensation, cytoplasmic shrinkage, 
dilated endoplasmic reticulum and membrane blebbing happen (Henkart, 1999). 
Apoptosis can be induced by different types of stimuli, including cell surface 
receptors like FAS, the mitochondrial response to stress, and factors released from 
cytotoxic T cells. For example, DNA damage may lead to apoptotic death via a 
p53-dependent pathway (Henkart, 1999). 
Intrinsic and extrinsic apoptotic pathways 
Two major pathways for activating caspases have been reported (Cory & Adams， 
2002). They are the intrinsic and extrinsic pathways. 
The extrinsic pathway, Fas, consists of several protein members, which include the 
death receptors, the membrane-bound Fas ligand, the Fas complexes, the 
Fas-associated death domain (FADD), and caspases 8 and 10 (Ghobrial, Witzig, & 
Adjei, 2005). Caspases 8 and 10 lead to apoptosis by activating the downstream 
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caspases (Ghobrial et al, 2005). This pathway is induced when 'death receptors' on 
the plasma membrane recruit caspase-8 through the adaptor protein FADD 
(Ashkenazi, 2002). 
The intrinsic pathway is regulated by the Bcl-2 family proteins (Cory & Adams, 2002). 
Programmed cell death through this pathway results in the caspase-9 activation on a 
scaffold which is formed by apoptotic protease-activating factor (Apafl) (Li et al., 
1997). Activation of caspase-9 occurs after Apafl has interacted with cytochrome c, 
which is released from damaged mitochondria (Li et al., 1997). 
Final pathway 
Both the intrinsic and extrinsic pathways lead to a common final pathway. The 
activation of caspases is the final pathway which leads to the execution of the death 
signal (Ghobrial et al., 2005). Caspase-3 is the common target of both the intrinsic 
and extrinsic pathways. Caspase-3 cleaves the inhibitor of the caspase-activated 
deoxyribonuclease, and it becomes active after cleavage, resulting in nuclear 
apoptosis (Ghobrial et al, 2005). Caspase-9 is the upstream caspase which converges 
to caspase-3 in the intrinsic pathway, while caspase-8 is the upstream caspase which 
converges to caspase-3 in the extrinsic pathway (Mancini et al., 1998; Thornberry & 
Lazebnik, 1998). The downstream caspases interfere with normal cell functions by 
triggering cleavage of protein kinases, cytoskeletal proteins, DNA repair proteins, 
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inhibitory subunits of endonucleaes (CIDE family), and ultimately, destroy 
"housekeeping" cellular functions (Mancini et aL,1998; Thomberry & Lazebnik, 
1998). Moreover, caspases affect cytoskeletal structure, regulation of cell cycle, and 
signaling pathways. It may lead to morphological signs of apoptosis, for example, 
DNA condensation, DNA fragmentation, and membrane blebbing. 
1.4.2 Caspases cascade 
The activation of caspases is one of the biochemical hallmark events of apoptosis 
(Thomberry & Lazebnik, 1998). Caspases inactivate proteins which prevent living 
cells from programmed cell death. Moreover, caspases lead to apoptosis by directly 
disassembling cell structures. Caspases cleave lamins at a single site during apoptosis. 
The cleavage may result in lamina collapse and subsequent chromatin condensation. 
Caspases mediate programmed cell death through an intricate mechanism. In most 
cells, caspases are found to be in inactive proenzyme form (Henkart, 1999). The 
inactive proenzymes require activation prior to execution of their enzyme activity. 
Activation of effector caspases 
Various biochemical evidences substantiate a cascade model for the activation of 
effector caspases (Thomberry & Lazebnik, 1998). The activation of an initiator 
caspase requires a pro-apoptotic signal (Thomberry & Lazebnik, 1998). When 
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activated initiator caspase activates effector caspases, cellular disassembly occurs. 
Initiator caspases mediate cell death by different signaling induced by different 
stimuli. For example, caspase-8 leads to apoptosis by binding to FADD (Ashkenazi & 
Dixit, 1998). Alternatively, caspase-9 is associated with programmed cell death 
induced by cytotoxic drugs (Filomenko et al., 2006). 
Activation of initiator caspases 
Biochemical evidences suggest that initiator caspases could bind to specific cofactors 
for activation, which is a commonly observed mechanism in proteases (Thornberry & 
Lazebnik, 1998). Binding of initiator caspases to specific cofactors is induced by a 
pro-apoptotic signal. This binding is mediated through distinct structural motifs, 
which is within both the caspase prodomain and its corresponding co factor. For 
example, procaspase-8 needs to associate with its cofactor FADD through the death 
effector domain (DED) for activation (Boldin, Goncharov, Goltseve, & Wallach, 1996; 
Muzio et al., 1996), while activation of procaspase-9 requires association with its 
cofactor APAF-1 through the caspase recruitment domain (CARD) to form a complex 
(Li et al., 1997). Furthermore, caspase-9 also requires cytochrome c and 
deoxyadenosine triphosphate for activation, which indicates multiple cofactors may 
be required for caspase activation (Thornberry & Lazebnik, 1998). 
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1.4.3 Bcl-2 family 
Bcl-2 family proteins regulate caspase activation; pro-apoptotic and anti-apoptotic 
protein members in the family determine the fate of the cell (Cory & Adams，2002). 
Bcl-2 family includes pro-apoptotic proteins such as Bax, Bak, Bad, Bid and etc., and 
anti-apoptotic proteins such as Bcl-2, BC1-XL and etc (Reed, 1994). Anti-apoptotic 
proteins repress apoptosis by blocking the release of cytochrome-c, while 
pro-apoptotic proteins promote the release of cytochrome-c (Reed, 1997). 
Pro-apoptotic proteins are modified post-translationally after receiving a death signal 
(Scorrano & Korsmeyer, 2003). These modifications include dephosphorylation and 
cleavage, which result in activation and translocation of these proteins, resulting in 
apoptosis (Scorrano & Korsmeyer，2003). To exert the intrinsic pro-apoptotic activity 
of BH3-only molecules, they need multi-domain BH3 proteins, such as Bax and Bak 
(Reed, 1994; Scorrano & Korsmeyer, 2003). The outer mitochondrial membrane 
becomes permeable upon apoptotic stimuli, resulting in the release of cytochrome-c 
and second mitochondria-derived caspase activator, which is also known as direct 
lAP-binding protein with low pi (Ghobrial et al., 2005). Once cytochrome-c is 
released in the cytosol and reacts with Apaf-1, it will lead to the activation of 
pro caspase-9 (Reed, 1997). The active caspase-9 cleaves procaspase-3, which 
subsequently activates the rest of the caspase cascade, resulting in apoptosis (Reed, 
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1997). Activated caspases lead to nuclear lamin cleavage, and nucleus breakdown 
through caspase-3 (Reed, 1997). 
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1.5 Apoptosis as a target of cancer therapy 
Since apoptosis is often defective in cancer, this could limit conventional therapy 
(Cory & Adams, 2002). A better understanding of apoptotic pathways is warranted to 
develop new and more effective therapeutic approaches (Cory & Adams, 2002). 
Several agents could directly or indirectly inhibit apoptosis-related proteins (Tamm, 
Schriever, & Dorken, 2001). These agents target apoptosis pathways or the regulators 
of apoptosis. For example, caspases activators, which target on caspases, are active in 
the common final death pathway (Ghobrial et. al, 2005). Moreover, the activation of 
pro-apoptotic protein, Bax, can be induced by gene therapy with the utilization of Bax 
vectors. Bcl-Xs gene therapy showed promising effects in inducing tumor regression 
(Ferreira, Epping, Kruyt, & Giaccone, 2002). 
The study of the intrinsic and extrinsic apoptotic pathways and other signaling 
modulators, such as the p53 showed that there were many effective novel agents on 
the pathways (Ghobrial et. al, 2005). These agents can function individually or in 
combination with conventional cytotoxic therapy or radiotherapy. Further research on 
different apoptotic signaling pathways in HCC can help the discovery of novel 
targeted agents, which affect the specific molecular defects of the tumor. 
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1.6 Aims of study 
To evaluate the potential role of berberine as an anti-cancer agent for hepatocellular 
carcinoma by in vitro study of the compound in different cancer cell lines in terms of 
cell viabilities, gene expression, protein expression and cell cycle distribution, and to 
understand the apoptotic pathways induced by berberine. 
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Chapter 2 Materials and Methods 
2.1 Cell culture and treatment 
2.1.1 Cell lines 
Huh? 
Huh7 is a well differentiated human hepatocellular carcinoma cell line. It was 
purchased from JCRB and was derived from a 57-year-old male. The ethnicity of the 
origin is Japanese. Cells were grown in Roswell Park Memorial Institute media 
(RPMI) 1640 with 10% of fetal bovine serum. 
JHH4 
JHH4 is a human hepatocellular carcinoma cell line. It was purchased from JCRB and 
was derived from a 51-year-old male. The ethnicity of the origin is Japanese. Cells 
were grown in Minimum Essential Media (MEM) with 10% of fetal bovine serum. 
WRL68 
WRL68 is a human liver embryonic cell line purchased from ATCC. Cells were 
grown in RPMI 1640 with 10% of fetal bovine serum. WRL68 cells have a 
morphologic structure similar to hepatocytes and hepatic primary cultures 
(Gutierrez-Ruiz et al. 1994). WRL68 is often used as a model for studying normal 
liver functions. 
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2.1.2 Berberine 
Berberine chloride was ordered from Sigma-Aldrich China, Inc. It was yellow 
powder. 
2.1.3 Chemicals and reagents 
Dulbecco's Phosphate Buffered Saline (DPBS), Fetal Bovine Serum (FBS), Penicillin 
Streptomycin antibiotic solution (PS), Roswell Park Memorial Institute (RPMI) 1640 
media, and Trypsin-EDTA (IX) were purchased from Invitrogen. Minimal Essential 
Media (MEM) were purchased from ATCC. Methylthiazolyldiphenyl-tetrazolium 
bromide (MTT) and sodium bicarbonate (NaHCOa) were from Sigma chemicals. St. 
Louis, USA. Dimethylsulfoxide (DMSO) was purchased from Fisher Scientific, USA. 
The filter millex-GP (0.22}im) was ordered from Millpore, Ma., USA. 75 cm^ tissue 
culture flasks were ordered from Corning, USA. 96-well microplates were purchased 
from Iwaki. 100mm culture dishes were purchased from Greiner Bio-one, Germany. 
2.1.4 Preparation of solutions 
Berberine stock solution (10 mM) 
Berberine stock solution was prepared by dissolving 0.0375g dry berberine chloride in 
10 ml of Milli-Q water. 
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DPBS 
Dulbecco's Phosphate Buffered Saline (DPBS) was ordered from Invitrogen and was 
stored at 4°C for cell culture use. 
MEM 
Liquid MEM was ordered from ATCC. Each liquid bottle contained 500 ml plain 
MEM. Plain MEM (50 ml) was drawn out before use. Fetal bovine serum (50ml) and 
PS antibiotic mixture (5 ml) were added to the liquid MEM. The completed medium 
was stored at 4°C. 
MTT solution 
MTT (5 mg) was dissolved in 1 ml of DPBS to give a final concentration of 5 mg/ml. 
MTT solution was freshly prepared before use, and was wrapped by aluminum foil to 
be protected from light. 
RPMI 
Liquid RPMI 1640 medium was ordered from Invitrogen. Each liquid bottle contained 
500 ml plain RPMI 1640 medium. Plain RPMI medium (50 ml) was drawn out before 
use. Fetal bovine serum (50 ml) and PS antibiotic solution (5 ml) were added to the 
liquid RPMI. The completed medium was stored at 4°C. 
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2.1.5 Procedures 
Seeding cells into culture flask 
Cells were seeded into culture flasks inside culture hood. Cells stored in liquid 
nitrogen stock were thawed in the 37°C incubation. Cells were transferred to a new 
falcon, and were re-suspended with additional fresh completed medium (5mL) and 
were centrifUged at 1000 rpm for 3 minutes. The supernatant was discarded, and the 
cell pellet was washed with 1 ml of DPBS, and was centrifuged at 1000 rpm for 3 
minutes. The supernatant was discarded and 1 ml of the completed medium was 
added to re-suspend cells. After re-suspension, cells were transferred to a new 75 cm 
culture flask with 12 ml of completed medium. The flask was stored in a 37°C 
incubator supplied with 5% carbon dioxide. 
Subculture of cells 
Subculture was done inside culture hood. The growth medium was discarded and 
warm DPBS was used to rinse the flask twice. Trypsin-EDTA (1 ml) was added to the 
flask and incubated at 37°C for 3 minutes. With appropriate tapping, cells were 
completely detached from the bottom surface of the flask. The completed medium (5 
ml) was added to stop the activity of trypsin. Cells were transferred to a new falcon 
and were centrifuged at 1000 rpm for 3 minutes. The supernatant was discarded and 
the cell pellet was re-suspended in 1 ml completed medium. After re-suspension, 2 jil 
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of cells were mixed with 18 \i\ of trypan blue and placed onto a hemocytometer. The 
cell count was performed with the use of a microscope. Cells were seeded in a new 75 
cm culture flask with 12 ml of fresh completed medium at the concentration of 1 x 
10 .^ The culture flask was stored in a 37°C incubator supplied with 5% carbon 
dioxide. 
Cell viability ossoy 
Huh7, JHH4 and WRL68 cells were seeded onto 96-well plate at the concentration of 
1 X 10^ overnight. Cells were treated with different concentration of berberine for 24, 
48，and 72 hours respectively. MTT solution (20 |iL) was added to each well of cells 
in the 96-well plate, and the plate was kept at 37°C with 5% carbon dioxide inside the 
incubator for 4 hours. After incubation, the medium was discarded and the plate was 
dried. DMSO (200 \iL) was added to dissolve the purple formazan formed. The plate 
was shaken for 3 minutes, after which the optical density was measured at 540 nm. 
Cell viability towards berberine was calculated by comparing the absorbance of wells 
of cells treated with different berberine concentration with the control. The 
concentration of berberine which reduced the cell viability by 50% ( I C 5 0 ) was 
recorded. 
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2.2 Apoptosis detection by FITC Annexin V and PI 
co-staining 
2.2.1 Chemicals and reagents 
FITC Annexin V Apoptosis Detection Kit I was ordered from BD Pharmingen'^^. 
The kit consisted of lOX Annexin V Binding Buffer, FITC Annexin V and Propidium 
Iodide Staining Solution. The reagents were stored undiluted at 4°C and protected 
from exposure to light. 
Dulbecco's Phosphate Buffered Saline (DPBS) was purchased from Invitrogen. 
2.2.2 Procedures 
Cells were harvested according to manufacturer's protocol 
Huh7 or JHH4 cells were grown to 60-80% confluence before treating with berberine. 
Cells were treated with different concentration of berberine for 24, 48, and 72 hours 
respectively. After berberine treatment, cells were harvested with trypsin. After 
washing with DPBS, cells were stained as recommended by BD Pharmingen^'^ FITC 
Annexin V Staining Protocol to measure apoptosis. The stained cells were analyzed 
using a FACSCanto instrument. Data were analyzed with the software FlowJo 7.6.1. 
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Modifications of the protocol 
Cells were treated according to the manufacturer's protocol with the modifications 
described below: 
1. FITC Annexin V was diluted with DPBS in the ratio of 1:3 prior to use. The 
reagent was freshly prepared. 5 was used per test. 
2. Propidium Iodide (PI) was diluted with DPBS in the ratio of 1:39 prior to use. 
The reagent was freshly prepared. An aliquot (5 |il) was used for each test. 
3. Annexin V Binding Buffer (lOX concentrate) was diluted with DPBS instead 
of distilled water. One part of the lOX Annexin V Binding Buffer was diluted 
to 9 parts of DPBS. 
Controls for setting up flow cytometry 
Controls below were used to set up compensation and quadrants for flow cytometry 
1. Unstained Huh7 and JHH4 cells. 
2. Huh7 and JHH4 cells stained with FITC Annexin V only. 
3. Huh7 and JHH4 cells stained with PI only. 
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2.3 Gene expression in Berberine画induced apoptotic cells 
2.3.1 Chemicals and Reagents 
Human Apoptosis RT^ Profiler PGR Array (PAHS-012) 96-well Plate and RT^ SYBR 
Green / ROX qPCR Master Mix were ordered from SABiosciences. RNase away was 
ordered from Invitrogen. RNase-free water was from USB, Cleveland, USA. RNeasy 
Mini Kit was ordered from Qiagen. Real-time PGR primers were ordered from 
Sigma-Aldrich. RT^ qPCR Primer Assay- SYBR ® Green Human ACTB, RT^ qPCR 
Primer Assay- SYBR ® Green Human CIDEA, and RT^ qPCR Primer Assay- SYBR 
® Green Human HRK were ordered from SABiosciences. Transcriptor First Strand 
cDNA Synthesis Kit was ordered from Roche Diagnostics. 
2.3.2 Procedures 
Cell treatments 
Huh7 or JHH4 cells were grown to 60-80% confluence prior to berberine treatment. 
Cells were treated with berberine for 72 hours. After incubation, cells were harvested 
with trypsin and centrifiiged at 1000 rpm for 3 minutes. 
Total RNA extraction 
Total RNA was isolated using RNeasy Mini kit (Qiagen) according to manufacturer's 
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protocol. RNA concentration was determined using Nano Drop spectrophotometer 
(Thermo Fisher Scientific). 
cDNA synthesis 
First-strand cDNA was synthesized using 1 [ig of total RNA using Transcriptor First 
Strand cDNA Synthesis Kit (Roche Diagnostics) according to manufacturer's protocol. 
Anchored-oligo(dT)i8 Primer was used in the template-master mix. 
PCR Array 
Experimental cocktail was prepared as recommended by 'RT Profiler^M PCR Array 
System Pathway-Focused Gene Expression Profiling Using Real-Time PCR’ Protocol. 
The cycling profile was as below: 
Cycles Duration Temperature 
1 10 minutes 95�C 
15 seconds 95°C 
40 
1 minute 60�C 
Real-time quantitations were performed using the Applied Bio systems 7500 
Real-Time PCR Systems. Ct values were calculated using the ABI system software. 
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Real-time PGR 
All Real-time PGR reactions were performed in a 10 fil mixture containing 0.4 |il of 
cDNA, 5 \i\ of RT2 SYBR Green / ROX qPCR Master Mix, 4 |il of RNase-free water 
and 0.4 |il of each primer. The cycling profile was as below: 
Cycles Duration Temperature 
1 10 minutes 95�C 
15 seconds 95�C 
40 
1 minute 60�C 
Real-time quantitations were performed using the Applied Bio systems 7500 
Real-Time PGR Systems. Ct values were calculated using the ABI system software. 
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2.4 Protein expression in Berberine-induced apoptotic cells 
2.4.1 Chemicals and Reagents 
Acrylamide, ammonium persulfate, bis-acrylamide, glycerol, glycine, hydrochloric 
acid (HCl), potassium chloride, sodium chloride, R o d e o E C L Western Blotting 
Reagents, TEMED and tris base were from USB, Cleveland, USA. Bromophenol blue, 
calcium chloride, sodium dodecyl sulfate (SDS), sodium azide, sodium vanadate (V), 
Tween-20 and p-mercaptoethano 1 were from Sigma chemicals, St. Louis, USA. BSA 
standard and DC Protein Assay were from Bio-rad. Methanol was from BHD. Non-fat 
milk powder was from Nestle. Primary antibodies used were listed below: GAPDH 
was ordered from Applied Bio systems. Bid was from BD Biosciences. Caspase-7, 
caspase-9, cleaved PARP, p53, and PARP were from cell signaling. Bcl-2, MDM2 and 
PCNA were from Santa Cruz. As for secondary antibodies, goat anti-mouse IgG (H+L) 
-HRP (Zymed®) was from Invitrogen, while anti-rabbit IgG, HRP-linked antibody 
was from Cell Signaling. PVDF membrane was from Pall. Rodeo™ ECL Western 
Blotting Reagents were from USB. 
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2.4.2 Preparation of solution 
The solutions used in protein expression studies were prepared as described below: 
1.5M Tris-HCl (pH 6.8) Tris base: 18.171g/100 ml 
pH was adjusted to 6.8 with HCl. 
10% Ammonium persulfate* Ammonium persulfate: O.lg/ ml 
10% SDS SDS: Ig/ml 
IM Tris-HCl (pH 8.8) Tris base: 12.114g/ 100ml 
pH was adjusted to 8.8 with HCl. 
1 OX SDS running buffer Tris Base: 30.2g/ L 
Glycine: 188g/L 
10% SDS: 100ml/L 
1 OX Tris-buffered saline (TBS) Sodium chloride: 88g/ L 
Potassium chloride: 2g/ L 
Tris base: 3g/ L 
1X Tris-buffered saline/ Tween 1 OX TBS: 100 ml/L 
(TBST) Tween-20: 1 ml/ L 
2X SDS sample buffer IM Tris (pH 6.8): 10ml/ 100ml 
10% SDS: 40ml/100ml 
Bromophenol blue: 0.2% 
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Glycerol: 20ml/ 100ml 
p-mercaptoethanol: 15|il/ 1ml 
30% Acrylamide/ Bis* Acrylamide: 29g/100ml 
Bis-acry lamide: Ig/ 100ml 
Blocking solution (5%) Non-fat milk powder: 0.2g/ 4ml 
Sodium azide: 0.05% 
BSA standard (4mg/ml)* * BSA standard: 4mg/ 1 ml whole cell lysis buffer 
Resolving gel 12% Milli-Q water: 1.28 ml 
l.SMTris (pH8.8): 1.04 ml 
30% Acrylamide/ Bis: 1.6 ml 
10% SDS: 40 
10% Ammonium persulfate: 40 \il 
TEMED: 5 [i\ 
Stacking gel 4% Milli-Q water: 1.48 ml 
0.5M Tris (pH 6.8): 1.25 ml 
30% Acrylamide/ Bis: 0.335 ml 
10% SDS: 25 i^l 
10% Ammonium persulfate: 12.5 [i\ 
TEMED: 5 fil 
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Transfer buffer Methanol: 200ml/ L 
Glycine: 2.93g/ L 
Tris: 5.82g/ L 
10% SDS: 3.75ml/L 
Whole cell protein lysis buffer SDS: 1% 
Sodium vanadate (V): ImM 
Tris: lOmM 
Calcium chloride: 5mM 
pH was adjusted to 7.4 with HCl. 
Remark: 
Solutions marked with * were stored at 4°C. 
Solutions marked with ** were stored at -20°C. 
2.4.3 Procedures 
Cell treatment 
Huh7 and JHH4 cells were seeded onto 100mm culture dish at the concentration of 1 
X 10^ overnight. Cells were treated with different concentration for 72 hours 
respectively. After berberine treatment, cells were harvested with trypsin and were 
centrifliged at 1000 rpm for 3 minutes. 
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Western Blot Analysis 
Cells were grown to 60-80% confluence in 100mm dishes followed by 72-hour 
treatment of different concentration of berberine. Whole cell lysates were extracted 
using whole cell lysis buffer. The protein concentration was determined by the DC 
Protein Assay (Bio-Rad) using BSA as the standard. 30|ig of protein was separated by 
SDS-PAGE and transferred for an hour onto a PVDF membrane (Pall). The blots were 
blocked with blocking solution (5%) for an hour, and were probed with a specific 
primary antibody with 5% non-fat milk powder in TBST at 4°C overnight. After 
washing with TBST, the blots were treated with the specific HRP-linked secondary 
antibody for an hour and were washed several times. Proteins were detected by 
Rodeo™ ECL Western Blotting Reagents (USB, Cleveland, USA) according to 
manufacturer's protocol. 
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2.5 Caspase cascade studies in berberine-induced apoptosis 
2.5.1 Chemicals and reagents 
Apo-ONE� Homogeneous Caspase-3/7 Assay was purchased from Promega. The 
assay consisted of 100|il Caspase Substrate Z-DEVD-RllO (lOOX) and 10ml 
Apo-ONE® Homogeneous Caspase-3/7 Buffer. 
2.5.2 Procedures 
Huh7 or JHH4 cells were seeded onto 96-well plate at the concentration of 1 x 10^  
overnight. Cells were treated with different concentration of berberine for 72 hours 
respectively. After berberine treatment, Apo-ONE® Homogeneous Caspase-3/7 assay 
was performed as recommended by 'Promega Technical Bullentin- Apo-ONE® 
Homogeneous Caspase-3/7 Assay Instructions for use of products G7790, G7791 
AND G7792'. The plate was incubated and shaken at room temperature for 2 hours. 
The fluorescence of each well was measured (excitation wavelength: 485nm; 
emission wavelength: 520nni). 
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2.6 Cell cycle study in berberine-induced apoptotic cells 
2.6.1 Chemicals and Reagents 
DPBS was purchased from Invitrogen. Ethanol was purchased from BDH. Propidium 
Iodide (PI) and Ribonuclease A from bovine pancreas (RNase A) were ordered from 
Sigma chemicals. St. Louis, USA. 5ml polystyrene round-bottom tubes were ordered 
from BD Falcon. 
2.6.2 Preparation of solutions 
PI of 40 }ig/ml was prepared with 100 fig/ml RNase A and was stored at -20°C in dark. 
70% (w/v) Ethanol was stored at -20°C. 
2.6.3 Procedures 
Cell treatments 
Huh7 or JHH4 Cells were grown to 60-80% confluence on 100mm culture dishes. 
Different concentration of berberine was added to the cells for 24, 48 and 72 hours. 
Fixing of cells 
Cells were harvested with trypsin after berberine treatment. Cells were washed with 
cold DPBS twice and were centrifiiged at 300 x g for 5 minutes. Next, cells were 
re-suspended in cold 70% (w/v) ethanol at a concentration of 1 x 10^  cells per ml. 
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Cells were suspended in ethanol at -20°C for 24 hours. After 24 hours, cells were 
centrifuged at 300 x g for 5 minutes. Ethanol was discarded and cell pellets were 
washed by cold DPBS. 
Staining of cells 
After the cold DPBS wash, cells were re-suspended with 400 \i\ of PI solution and 
transferred to a 5ml polystyrene round-bottom tube. The tube was incubated for 15 
minutes at 25°C in dark. Tubes were analyzed by BD FACSCanto flow cytometer 
within 1 hour. 
Data analysis 
FACSDiva software was used to operate BD FACS Canto Flow Cytometer. 
Experimental data were captured and were analyzed by FlowJo 7.6.1. The percentage 
of populations in Gi, G2 and S phases of cell cycle was recorded. The experiment was 
performed three times. The ratio of cells in the Gq/Gi, intra-S, and G2/M phases were 
expressed as mean 士 SD. 
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Chapter 3 Results 
3.1 Berberine induces apoptosis in hepatocellular cells 
Effects of berberine on hepatocellular carcinoma (HCC) cell lines were evaluated by 
the MTT assay. HCC cell lines used for the study were Huh7 and JHH4, while normal 
liver cell line WRL68 was used as a control experiment. The results indicate that 
berberine showed inhibitory effect towards the growth of HCC cells. 
Apoptosis in HCC cell lines were detected by BD PharmingenTM PITC Annexin V 
Apoptosis Detection Kit I. FITC Annexin V is often used together with propidium 
iodide (PI) to allow the identification of early apoptotic cells, which yield PI negative 
and FITC Annexin V positive signals (Koopman G et al., 1994). 
The treatment concentration in FITC Annexin V-PI co-staining for Huh? cells was 0, 
5，10, and 20 |iM. IC50,72h (half maximal inhibitory concentration at 72 hours) of 
berberine in Huh7 was 10 |iM. An intermediate dose of 5 fiM, and a higher dose of 20 
fiM, was used for comparing effects of berberine in Huh7 cells at different 
concentration. For JHH4, the treatment concentration was 0, 15, 30, and 60 fiM. IC50, 
72h of berberine in JHH4 was 30 fiM. An intermediate dose of 15 fiM, and a higher 
dose of 60 fiM, was used for comparing effects of berberine in JHH4 cells at different 
concentration. The results demonstrate that berberine caused apoptosis in HCC cells. 
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Figure 2 Viabilities of (A) Huh7, (B) JHH4, and (C) WRL68 treated with berberine for 
24, 48 and 72 hours 
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Evaluation of the cell viability of Huh7, JHH4 and WRL68 cells treated with berberine 
for 24, 48 and 72 hours 
Huh7 cells (Figure 2A), JHH4 cells (Figure 2B) and WRL68 (Figure 2C) cells were 
incubated with 0-1000 fiM berberine for 24, 48 and 72 hours respectively. The 
percentage of viable cells was determined using the MTT assay as mentioned in 
Materials and Methods. Control cells were treated with vehicle only. The above 
experiments were performed in triplicate and the data represent the means 士 SD. The 
IC50 for each cell line at each treatment length was recorded in the tables below. 
Huh7 (Figure 2A): 
Time (hour) 24 48 72 
I C 5 o ( _ 150 100 10 
JHH4 (Figure 2B): 
Time (hour) 24 48 72 
I C 5 o ( _ 105 60 30 
WRL68 (Figure 2C): 
Time (hour) 24 48 72 
I C 5 o ( _ 1000 120 100 
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Figure 3 Apoptotic cells after (A) 24-hour, (B) 48-hour, and (C) 72-hour berberine 
treatment in Huh7 cell line 
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Berberine leads to apoptosis in Huh7 cells 
BD Pharmingen丁M FITC Annexin V Apoptosis Detection Kit I was used to detect 
apoptosis in Huh7 cells. The experiment was done according to manufacturer's 
protocol with modifications (Chapter 2.2). 
Huh7 cells were seeded into 6-well plates. Cells were treated with Berberine at 0, 5, 
10 and 20 \iM for 24, 48, and 72 hours respectively. The results with triplicate 
experiments (* P < 0.05; ** P < 0.01 ) were shown in Figure 3. 
For Huh7 cells treated with berberine for 24 hours (Figure 3A), the percentage of 
apoptotic cells increased along with the increase in berberine concentration. For Huh7 
cells treated with berberine for 48 hours and 72 hours (Figure 3B and Figure 3C), the 
treated cells showed a significant increase in the percentage of apoptotic cells 
compared with the untreated cells. 
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Figure 4 Apoptotic cells after (A) 24-hour, (B) 48-hour, and (C) 72-hour berberine 
treatment in JHH4 cell line 
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Berberine leads to apoptosis in JHH4 cells 
Cells were treated with Berberine at 0, 15, 30 and 60 \xM for 24, 48, and 72 hours 
respectively. The results with triplicate experiments (** P < 0.01; *** P < 0.001 ) 
were shown in Figure 4. 
For 24-hour (Figure 4A), 48-hour (Figure 4B), and 72-hour (Figure 4C) berberine 
treatment, the treated cells showed a significant increase in the percentage of 
apoptotic cells compared with the untreated cells. 
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3.2 Gene expression in Berberine-induced apoptotic cells 
Gene expression in HCC cell lines were studied by PGR array and real-time PGR. 
PCR array was used to profile the gene expression in Huh7 cells. Real-time PGR was 
used as a quantitative experiment to study the gene expression in berberine-treated 
HCC cells. 
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Figure 5 Apoptosis PCR Array profiled Up- or Down- Regulated Genes in Huh7 cells 
upon 72-hour berberine treatment 
Apoptosis PCR Array profiled apoptotic genes in various apoptotic signaling 
pathways. Experimental Huh7 cells were treated with 10 fiM berberine for 72 hours, 
and control Huh7 cells were treated with vehicle for 72 hours. Total RNA from 
untreated Huh7 cell and berberine-treated Huh7 cell were characterized. cDNA was 
synthesized from the total RNA as mentioned in Chapter 2.3.2. The relative 
expression levels for each gene in both samples were plotted against each other in the 
Scatter Plot using the program provided by the manufacturer. The middle line 
indicates fold changes ((2a(-A Ct)) of 1. The left and right lines indicate the 
fold-change in gene expression threshold, which was defined at 3-fold. Outliers of the 
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left line were genes up-regulated by at least three-fold, which included BCL2, 
BCL2L1, CASP14, CD40, CIDEA, FASLG, GADD45A, HRK, LTA, TNFRSFIOA, 
TNFRSFIOB, CD27, TNFRSF9, and CD70. The outliner of the right line was 
BCLAFl, which was down-regulated by at least three-fold. 
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Figure 6 Real-time PCR result showed berberine regulated expression of genes in 
Huh7 cells in a dose-dependent manner 
Total RNA from untreated Huh7 cells and berberine-treated Huh7 cells were 
characterized. Cells were treated with berberine at different concentration for 72 hours. 
After 72 hours, total RNA was extracted and cDNA was synthesized from the total 
RNA. Real-time PCR was done according to the procedure mentioned in Chapter 
2.3.2. Bax, Bid, CIDEA, HRK, and p21 were found to be up-regulated by berberine in 
a dose-dependent manner, while AKT and Bcl-2 were found to be down-regulated by 
berberine in a dose-dependent manner. The gene expression of Survivin decreased 
along with the increase in berberine concentration. The data represent the mean 士 SD 
of three individual experiments (** P < 0.01 ). 
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Figure 7 Real-time PCR result showed berberine regulated expression of genes in 
JHH4 cells in a dose-dependent manner 
Total RNA from untreated JHH4 cells and berberine-treated JHH4 cells were 
characterized. Cells were treated with berberine at different concentration for 72 hours. 
After 72 hours, total RNA was extracted and cDNA was synthesized from the total 
RNA. Real-time PCR was done according to the procedure mentioned in Chapter 
2.3.2. Bax, Bid, CIDEA, HRK, and p21 were found to be up-regulated by berberine in 
a dose-dependent manner, while AKT and Bcl-2 were found to be down-regulated by 
berberine in a dose-dependent manner. An increase in berberine concentration did not 
affect the gene expression of Survivin. The data represent the mean 士 SD of three 
individual experiments (* P < 0.05 ). 
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3.3 Caspase cascade studies in berberine-induced apoptosis 
Apo-ONE ® Homogeneous Caspase-3/7 Assay Kit was used to measure caspase3/7 
activities of the HCC cells after Berberine treatment. The assay measured the 
non-fluorescent caspase substrate Z-DEVD-RllO that is cleaved by Caspase-3/7, 
producing the fluorescent Rhodamine 110. Fluorescence generated in the experiment 
is proportional to the amount of caspase-3/7 cleavage activity present in the cultured 
sample. 
Protein members in caspase cascade were studied by SDS-PAGE and Western Blot 
Analysis. For Huh7, treatment concentration was 0, 5, 10, and 20 |iM. IC50,72h of 
berberine in Huh7 was 10 fiM. An intermediate dose of 5 |iM, and a higher dose of 20 
\iM, was used for comparing effects of berberine in Huh7 cells at different 
concentration. For JHH4, treatment concentration was 0, 15, 30, and 60 |iM. IC50 ,72h 
of berberine in JHH4 was 30 |iM. An intermediate dose of 15 fiM, and a higher dose 
of 60 fiM, was used for comparing effects of berberine in JHH4 cells at different 
concentration. 
In the Western Blot Analysis, GAPDH was used as the control protein. Intensities of 
bands were analyzed by Image J. Normalization of GAPDH was included in the 
analysis. 
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Figure 8 Caspase-3/7 activities in Huh7 andJHH4 cells 
Evaluation of cospose3/7 activities of Huh7 in JHH4 cells treated with berberine for 72 
hours 
Apo-ONE ® Homogeneous Caspase-3/7 Assay Kit was used to measure caspase3/7 
activities of the HCC cells after Berberine treatment. Huh7 or JHH4 cells were seeded 
into 96-well plates. Cells were either remained untreated or treated with Berberine at 
30 |iM for 72 hours. The treatment dose was designated as 30 |iM because it was the 
IC50,72h in JHH4 cells. After treatment, caspase substrate Z-DEVD-RllO was added 
according to the assay kit protocol. The fluorescence was measured with the 
excitation wavelength at 495mn, and the emission wavelength at 595nm. 
The data represent the mean 士 SD of three individual experiments (*** P < 0.001 ). 
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Figure 9 Western Blot Analysis of Procospase-9, Procaspase-7, and Procaspase-3 in 
Huh7 cells after 72-hour berberine treatment at different concentration 
GAPDH was used as the control protein. Intensities of bands were analyzed by Image 
J. Figure 9 showed the representative experimental results of three experiments. The 
results suggest the expression of procaspase-9, and its effector caspases, procaspase-7 
and procaspase-3 in Huh7, was decreased along with the increase in berberine 
concentration. 
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Figure 10 Western Blot Analysis of Procospose-9, Procospose-7, and Procaspase-3 in 
JHH4 cells after 72-hour treatment at different concentration 
GAPDH was used as the control protein. Intensities of bands were analyzed by Image 
J. Figure 10 showed the representative experimental results of three experiments. The 
results show the expression of procaspase-9, and its effector caspases, procaspase-7 
and procaspase-3 in JHH4, was decreased along with the increase in berberine 
concentration. 
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3.4 Protein expression in Berberine-induced apoptotic cells 
The protein expression was studied in both Huh7 and JHH4 cells. The expression of 
Bcl-2 protein family members such as Bcl-2 and Bid, and other proteins including 
PARP and PCNA was studied by SDS-PAGE and Western Blot Analysis. 
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Figure 11 Western Blot Analysis of PARP, cleaved PARP, PCNA, Bid, and Bcl-2 in Huh? 
cells after 72-hour berberine treatment at different concentration 
GAPDH was used as the control protein. Intensities of bands were analyzed by Image 
J. Figure 11 showed the representative experimental results of three individual 
experiments. The results indicate that berberine caused cleavage of PARP, which is an 
important apoptosis marker, after 72-hour treatment. The expression of PCNA, Bid, 
and Bcl-2 in Huh7 was decreased along with the increase in berberine concentration. 
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Figure 12 Western Blot Analysis of PARP, cleaved PARP, PCNA, Bid, and Bcl-2 in JHH4 
cells after 72-hour berberine treatment at different concentration 
GAPDH was used as the control protein. Intensities of bands were analyzed by Image 
J. Figure 12 showed the representative experimental results of three individual 
experiments. The results indicate that berberine caused cleavage of PARP, which is an 
important apoptosis marker, after 72-hour treatment. The expression of PCNA, Bid, 
and Bcl-2 in JHH4 was decreased along with the increase in berberine concentration. 
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3.5 Berberine causes Gi cell cycle arrest in HCC cell lines 
Flow cytometry was used to study if berberine could cause cell cycle arrest. The 
results show that there was an increase of Gi cell population along with the increase 
in the concentration of berberine, suggesting that berberine causes Gi cell cycle arrest 
in both Huh7 and JHH4 cell lines. The cell cycle was studied at three time points: 24, 
48, and 72 hours, respectively. 
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Figure 13 The cell cycle distribution of Huh-7 cells after berberine treatment for 24 
hours 
Huh-7 cells were treated with different concentration, (A) 0 fiM, (B) 5 |iM, (C) 10 
}xM, and (D) 20 fiM. Figure 13 showed the representative experimental results of 
three individual experiments. The results suggest that berberine caused Gi/S cell cycle 
arrest in Huh-7 cells after 24-hour treatment. 
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Figure 14 The cell cycle distribution of Huh-7 cells after berberine treatment for 48 
hours 
Huh-7 cells were treated with different concentration, (A) 0 |LIM, (B) 5 \xM, (C) 10 
|iM, and (D) 20 ^iM. Figure 14 showed the representative experimental results of 
three individual experiments. The results indicate that berberine caused Gi/S cell 
cycle arrest in Huh-7 cells after 48-hour treatment. 
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Figure 15 The cell cycle distribution of Huh-7 cells after berberine treatment for 72 
hours 
Huh-7 cells were treated with different concentration, (A) 0 \xM, (B) 5 |iM, (C) 10 
|iM, and (D) 20 fiM. Figure 15 showed the representative experimental results of 
three individual experiments. The results show that berberine caused Gi/S cell cycle 
arrest in Huh-7 cells after 72-hour treatment. 
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Figure 16 The cell cycle distribution ofJHH-4 cells after berberine treatment for 24 
hours 
JHH-4 cells were treated with different concentration, (A) 0 fiM, (B) 15 fiM, (C) 30 
|iM, and (D) 60 f i M . Figure 16 showed the representative experimental results of 
three individual experiments. The results demonstrate that berberine caused Gi/S cell 
cycle arrest in JHH-4 cells after 24-hour treatment. 
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Figure 17 The cell cycle distribution ofJHH-4 cells after berberine treatment for 48 
hours 
JHH-4 cells were treated with different concentration, (A) 0 fiM, (B) 15 \xM, (C) 30 
^M, and (D) 60 fxM. Figure 17 showed the representative experimental results of 
three individual experiments. The results indicate that berberine caused Gi/S cell 
cycle arrest in JHH-4 cells after 48-hour treatment. 
CHAPTER 3 RESULTS 71 
A: 0 ^ M B: 15 i^M 
. 300 -
“ i : I 
1 5 0 - J I 
• 2 0 0 -§ : 1 Gi 
O o 1 ^ too- j o . 
u I I T ""[""1圓丨丨I|丨丨丨丨丨丨I丨丨丨丨丨I|"M| ."u|iiiii.iri.m.i|iii.iii|'<i*r I I~rn—•r^ U I I F " t i ' ‘i"'" |" "1" i "'「.印^  i~i—|~r—i~r^ 
0 200 400 600 8 00 IK 0 200 400 600 800 IK 
PE-A PE-A 
C: 30 扑M D: 60 ^ M 
i 250 -
： I ： 
200 -
200 -
1 5 0 - j ： 
E G, § Gi o o O I o 
too -
• 1 0 0 -
� . . � i h i / X ^ , 。：: J z W A ^ , 
u _ I I r I I ' I t , I I.I 『|| r ' [' I I " • 1 圓 I I I Y * U - I I < 1 ,f I I y . I- ii ,1111111, III i|iiii.i|ii 1111,111 I r - i — r - Y " 
0 200 400 600 800 1K 0 200 400 600 800 1K 
PE-A PE-A 
Figure 18 The cell cycle distribution ofJHH-4 cells after berberine treatment for 72 
hours 
JHH-4 cells were treated with different concentration, (A) 0 \iM, (B) 15 [iM, (C) 30 
fiM, and (D) 60 \iM. Figure 18 showed the representative experimental results of 
three individual experiments. The results suggest that berberine caused Gi/S cell cycle 
arrest in JHH-4 cells after 72-hour treatment. 
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Figure 19 The cell cycle distribution (%) of Huh7 cells after treatment with berberine 
for (A) 24 hours, (B) 48 hours, and (C) 72 hours 
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Flow cytometric analysis of cell cycle in Huh? cells after berberine treatment 
Cell cycle arrest was studied by propidium iodide (PI) staining. Huh7 cells were 
treated with berberine at the concentration of 0, 5, 10 and 20 |iM for 72 hours, 
respectively. Cells were harvested after treatment, and were fixed with 70% ethanol 
overnight. After fixation, cells were stained with PI and were subject to analysis by 
flow cytometry. 
Figure 19A and Figure 19B showed that there was a slight increase in percentage of 
cells in Gi phase along with the increase in berberine concentration, after 24-hour and 
48-hour treatment, respectively. Figure 19C demonstrated that the percentage of cells 
in Gi phase in 5, 10, and 20 |iM increased by 10% at least compared with that in 0 
fiM berberine treatment. The results in Figure 19 suggest that berberine triggered Gi 
cell cycle arrest in Huh7 cells ( n = 3; *** P< 0.001 ). 
CHAPTER 3 RESULTS 74 
A: 24-hour 
1 0 0 - , 少-少-女 
o 國 0 ^M 
2 80- n E a 15 ^ M 
白 由 _ S 30 mM 
芸 _ S • [H ] 6 0 pM 
^ S a 1 
& 40- _ § • 
0 V E IS89 C" 一 dtAdt = fi = *** 
。 2 0 _ 圏 多 三 工 
S � I I I l l l f f i M m 
U I p 




1 漏 OmM 
1 80- 面 15 ^M 
% 份 目 3 0 fiM 
I 60- ^ t t g f f l Dm 60 ^M 
_c> 圏 笠 = 
呈 40- _ g • 
o 圓 S = *** 
S jmm i H l l l 圓隨圓III 





芸 8 0 - 女矢女 國 0 fiM 
'B 工 工 EE3 15 ^ M 
1 40- 1 M _ 60 MM 
= H f = T X e i T i 
o 20- ^ y 三 *** = 
S 0 1 1 1 , 1 1 1 1 1 1 . 1 1 1 -
G1 S G2 
Phase 
Figure 20 The cell cycle distribution (%) of JHH4 cells after treatment with berberine 
for (A) 24 hours, (B) 48 hours, and (C) 72 hours 
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Flow cytometric analysis of cell cycle in JHH4 cells after berberine treatment 
Cell cycle arrest was studied by propidium iodide (PI) staining. JHH4 cells were 
treated with 0, 15, 30 and 60 \xM berberine for 72 hours, respectively. Cells were 
harvested after treatment, and were fixed with 70% ethanol overnight. After fixation, 
cells were stained with PI and were subject to analysis by flow cytometry. 
Figure 20A and Figure 20C demonstrated that as the percentage of cells in Gl phase 
increased along with the increase in berberine concentration after 24-hour and 
72-hour treatment, respectively. Figure 20B showed there was a slight increase in 
percentage of cells in Gi phase along with the increase in berberine concentration 
after 48-hour treatment. 
The results in Figure 20 suggest that berberine triggered Gi cell cycle arrest in JHH4 
cells ( n = 3; *** P< 0.001 ). 
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Chapter 4 Discussion 
Berberine showed inhibitory effect towards the proliferation of HCC cells 
In this study, berberine was shown to significantly inhibit proliferation of HCC cells, 
and reduce cell viabilities in a dose-dependent manner. Berberine did not show 
significant inhibitory effect on normal liver cells upon 24-hour treatment, and it 
exhibited inhibitory effect on normal liver cells at a lesser extent upon 48-hour and 
72-hour treatment, compared with that in Huh7 and JHH4 cells. Berberine exhibited 
more potent effect after 72-hour treatment with berberine in both Huh7 and JHH4 cell 
lines. The half maximal inhibitory concentration ( IC50) of berberine in Huh7 after 
72-hour treatment was 10 \iM; while the IC50 of berberine in JHH4 after 72-hour 
treatment was 30 |LIM. IC50 of berberine in W R L 6 8 after 72-hour treatment was 100 
|iM. The results suggest that HCC cell lines and normal liver cells may show different 
cellular response towards berberine. The fact that Huh7 and JHH4 have different IC50 
of berberine treatment suggests their difference in cellular response towards berberine. 
Berberine could induce apoptotic effects on HCC cells and consequently, it causes 
apoptotic death in HCC cells but not in normal liver cells. The difference in inhibitory 
activities towards cancer cells and normal cells suggests berberine could be a good 
apoptotic agent in HCC cells. 
While comparing berberine with traditional drugs used in chemotherapy, such as 
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doxorubicin, the IC5o,72h of doxorubicin in HepG2 was 1 |iM (Al-Qubaisi et al” 2011), 
while the IC50,72h of doxorubicin in Chang liver cell was less than 1 |iM (Al-Qubaisi 
et al., 2 0 1 1 ) . Although doxorubicin has a very low IC50 , it has a low therapeutic index, 
and its clinical use is limited since it leads to acute and chronic toxicities 
(Bandyopadhyay et al., 2010). It is imperative to find an alternative agent for cancer 
treatment. The results in the present study suggest that berberine should be a suitable 
candidate since it did not produce toxic effects and it showed specific activity towards 
liver cancer cells, while its effects on normal liver cells were not observable at the 
same concentration. Considering the IC50,72h of berberine in Huh7 and W R L 6 8 , it 
may require 10-fold increase in concentration for berberine to produce a toxic effect 
in normal cells. 
FITC Annexin V and PI co-staining showed that berberine caused apoptosis in HCC 
cells 
The loss of membrane integrity occurs during the latest stages of cell death either 
from apoptosis or necrosis (Koopman G et al., 1994). FITC Annexin V staining is 
succeeded by the loss of membrane integrity; therefore, FITC Annexin V staining is 
often used together with vital dyes such as propidium iodide (PI) (Koopman G et al., 
1994). The FITC Annexin V and PI co-staining technique allows the identification of 
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early apoptotic cells, which yields PI negative and FITC Annexin V positive signals 
(Koopman G et al., 1994). FITC Annexin V and PI co-staining provides experimental 
evidences (Figure 3 and Figure 4) that berberine caused apoptosis in both Huh7 and 
JHH4 cells. For Huh7 cells, the 72-hour treatment (Figure 3C) resulted in a lower 
percentage of apoptotic cells compared with the 24-hour treatment (Figure 3A). The 
phenomenon may be explained by more cell death after 72-hour berberine treatment 
than that after 24-hour berberine treatment. Cells may undergo early apoptotic process 
after 24-hour berberine treatment, while after 72-hour treatment cells may have died 
via apoptosis. In this way, less percentage of apoptotic cells would be observed. 
For JHH4 cells, a significant higher percentage of apoptotic cells was observed in 
treated cells for 24-hour (Figure 4A), 48-hour (Figure 4B), and 72-hour (Figure 4C) 
berberine treatment compared with the untreated cells. 
Berberine regulated gene expression in HCC cell lines 
In this study, PCR array was used as a preliminary screening procedure for genes that 
were affected by berberine significantly (Figure 5). The gene expression of Bcl-2, 
CIDEA and HRK were validated by Real-time PCR. The real-time PCR results 
corroborated with PCR Array analysis for CIDEA gene. CIDE family is known as the 
inhibitory subunits of endonucleaes, cleavage of which is induced by downstream 
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caspases (Ghobrial et al., 2005). 
In real-time PGR results for both Huh7 and JHH4 cells (Figure 6 and Figure 7), Bax, 
Bid, CIDEA, HRK，and p21 were found to be up-regulated by berberine in a 
dose-dependent manner, while AKT and Bcl-2 were found to be down-regulated by 
berberine in a dose-dependent manner. 
Al l BH3-only molecules need Bax, which is a multi-domain BH3 protein, to exert 
their intrinsic pro-apoptotic activity (Ghobrial et al., 2005). In response to apoptotic 
stimuli, Bax is an essential gateway to mitochondrial dysfiinction required for cell 
death (Wei et al., 2001). An increase in the gene expression of Bax suggests an 
increased protein expression of Bax, which is crucial to the intrinsic apoptotic 
pathway. The p21 gene codes for the cyclin-dependent kinase inhibitor 1 
(CDK-interacting protein 1). The p21 protein serves as a regulator of cell cycle 
progression at Gi phase (Luo et al., 1995). An increase in p21 gene expression (Figure 
6 and Figure 7) suggests an increased protein expression of p21 protein, the 
transcriptional target of the tumor suppressor protein p53 (El-Deiry et al., 1993). 
AKT protein takes part in the regulation of tumor cell survival and proliferation by 
stabilizing p21 protein (Li, Dowbenko, & Lasky, 2002). When AKT gene expression 
decreased (Figure 6 and Figure 7), it suggests that less AKT protein would be 
expressed. A decreased AKT protein expression suggests less inhibition of p21 protein 
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activity, which results in cell cycle arrest at Gi phase. Bcl-2 gene is over-expressed in 
certain cancers, such as folicular B-cell lymphoma, chronic lymphocytic leukemia, 
and B-cell non-Hodgkin lymphomas (Ghobrial et al., 2005). While Bcl-2 gene 
expression was found to be decreased in the present study, the result suggests that 
berberine may inhibit the gene expression of Bcl-2 gene in HCC cells. Bid is a 
well-known pro-apoptotic protein player in the Bcl-2 family, which requires 
proteolytical cleavage to become active (Li et al., 1998). An increased gene 
expression of Bid implies an increased protein expression of Bid in the cytosol, while 
the activity of Bid in the cytosol should be evaluated by protein expression analysis. 
Survivin is an anti-apoptosis gene expressed in cancer and lymphoma (Ambrosini, 
Adida, & Altieri, 1997). Survivin gene codes for the protein Survivin, which belongs 
to the inhibitor of apoptosis (lAP) family. Survivin negatively regulates apoptosis by 
inhibiting caspase activation. Survivin gene is a potential apoptosis-based therapeutic 
target. The findings from the present study demonstrated that berberine may inhibit 
Survivin gene expression in Huh7, while berberine did not affect the expression of 
Survivin gene expression in JHH4 significantly. 
The real-time PGR results agreed with PGR Array analysis for HRK gene. The HRK 
gene encodes the protein, activator of apoptosis harakiri (Inohara, Ding, Chen, & 
Nunez, 1997). Early studies showed that the expression of HRK induced cell death 
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which was inhibited by Bcl-2 and Bcl-X(L) (Inohara et al., 1997). While berberine 
up-regulated the expression of HRK gene (Figure 6), more HRK protein may be 
expressed, which may increase apoptotic cell death. 
The Bcl-2 gene expression was found to be down-regulated by berberine in real-time 
PGR experiments. Early studies reported that increased Bcl-2 protein expression 
causes resistance to chemotherapeutic drugs and radiation therapy, while decreasing 
Bcl-2 expression may promote apoptosis induced by anti-cancer drugs (Ghobrial et al., 
2005). Furthermore, over-expression of Bcl-2 may cause accumulation of cells in the 
Go phase of cell cycle division, resulting in chemoresistance (Reed, 1997). The 
present study provides experimental evidences that berberine negatively regulated the 
protein expression of Bcl-2. The results suggest that berberine may cause apoptosis in 
HCC cells through the intrinsic apoptotic pathway. 
Caspase3/7 activities in Huh? anclJHH4 cells 
Caspase-3/7 activities in both Huh7 and JHH4 cells were evaluated by Apo-ONE ® 
Homogeneous Caspase-3/7 Assay Kit. The principle of the assay is that the 
non-fluorescent caspase substrate Z-DEVD-RllO is cleaved by Caspase-3/7 to create 
the fluorescent Rhodamine 110. The fluorescence generated in the experiment is 
proportional to the amount of caspase-3/7 cleavage activity present in the cultured 
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sample. The results indicate berberine triggered caspase-3/7 activities in both HCC 
cell lines. Among Huh7 and JHH4 cell lines, higher caspase-3/7 activities were 
observed in Huh7. The results suggest Huh7 and JHH4 cells may exhibit different 
cellular response towards berberine. The protein expression of caspase-3 and 
caspase-7 was further evaluated by SDS-PAGE and Western Blot Analysis. 
Protein expression studies showed that berberine caused apoptosis through Cospase 
Cascade 
In the present study, the protein expression studies were focused on caspase cascade 
and the Bcl-2 protein family. The results suggest that berberine induces apoptosis 
through the intrinsic apoptotic pathway. While the release of cytochrome c from 
mitochondria begins, the mitochondrial stress pathway is activated (Earnshaw, 
Martins, & Kaufinann, 1999). Cytochrome c interacts with Apaf-1, which activates 
caspase-9 (Earnshaw et al., 1999). The effector caspases, caspase-7, and caspase-3 are 
downstream targets of caspase-9 (Earnshaw et al., 1999). Poly (ADP-ribose) 
Polymerase (PARP) is a well-known downstream target of active caspase-3 (Boulares 
et al., 1999). While apoptosis is induced in cells, PARP can be cleaved (Boulares et al., 
1999). PARP was reported to produce poly(ADP-ribosyl)ation of nuclear proteins 
with NAD as substrate (Boulares et al., 1999). It was shown to cause cell death by 
CHAPTER 4 DISCUSSION 83 
depleting NAD and ATP of the cell, as it is activated through binding to DNA ends or 
strand breaks (Boulares et al., 1999). Previous studies revealed that during 
drug-induced apoptosis in different cells, PARP was shown to be cleaved into 
fragments which contain the active site as well as the DNA-binding domain of the 
enzyme (Boulares et al., 1999). PARP is inactivated by such cleavage as its ability to 
respond to DNA strand breaks is destroyed (Boulares et al” 1999). The present study 
enables us to confirm that berberine caused apoptosis in HCC cells through the 
intrinsic caspase-mediated pathway. The protein expression of full-length PARP 
decreased while cleaved form of which increased. Since berberine decreased the 
protein expression of procaspase-9, and its downstream effector caspases, 
procaspase-3 and procaspase-7, it may be possible that berberine cleaves caspase-9, 
caspase-3 and caspase-7. Cleaved caspases become active executioners of the intrinsic 
apoptotic pathway. 
The intrinsic apoptosis pathway is also regulated by Bcl-2 protein family. The study 
showed that Bcl-2, an anti-apoptotic member in the Bcl-2 protein family, was 
down-regulated by berberine in dose-dependent fashion in both Huh7 and JHH4 cells 
after 72-hour treatment (Figure 11 and Figure 12). The results indicated that the 
expression of another pro-apoptotic member in the Bcl-2 protein family, Bid, was 
down-regulated after treating with berberine for 72 hours, in both Huh7 and JHH4 
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cells. Bid is a BH3 domain-containing pro-apoptotic Bcl-2 protein family member, 
which is a mediator of mitochondrial damage induced by caspase-8 (Li, Zhu, Xu, & 
Yuan, 1998). Full-length Bid is localized in cytosol, while truncated Bid (tBid) 
translocates to mitochondria (Li et al., 1998). Transduction of apoptotic signals from 
cytoplasmic membrane to mitochondria is mediated by tBid (Li et al., 1998). tBid was 
reported to induce the clustering of mitochondria around the nuclei and release of 
cytochrome c in a caspase-independent fashion, and then the loss of mitochondrial 
membrane potential, cell shrinkage, and condensation of nuclei in a 
caspase-dependent manner (Li et al., 1998). 
The present study demonstrated that the protein expression of Bid in cytosol was 
decreased with increasing concentration of berberine, while the gene expression of 
Bid was increased with berberine treatment in a dose-dependent manner; a possible 
explanation is that Bid in cytosol was truncated and was translocated to mitochondria. 
Upon this translocation, it was likely that tBid led to the apoptotic consequence 
afterwards. Further investigation of the protein expression of tBid (which has a 
molecular size of 15 kDa) in mitochondria is recommended to gain a more complete 
understanding of biologic activity of berberine in the intrinsic apoptotic pathway. 
The protein expression of proliferating cell nuclear antigen (PCNA) was found to be 
down-regulated by berberine in both Huh7 and JHH4 cells in a dose dependent 
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manner after 72-hour treatment. Previous studies showed that PCNA is essential for 
both DNA synthesis and DNA repair (Shivji, Kenny, & Wood, 1992). The 
experimental results imply that as the expression of PCNA was reduced by berberine, 
fewer cells were able to repair damaged DNA. 
Berberine caused Gj/S cell cycle arrest in both Huh? and JHH4 cells 
The findings from the present study provide supportive evidences that berberine 
caused Gi/S cell cycle arrest in HCC cell lines (Figure 19 and Figure 20). Gi is the 
first cell cycle checkpoint, which determines whether the cell should divide, delay 
division, or enter a resting stage, before the cells entering into S phase. The results 
suggest berberine may stop HCC cells from dividing, thereby halting the deregulated 
cell proliferation. 
Conclusion 
The present study has demonstrated that berberine inhibits growth of HCC cells by 
inducing the intrinsic apoptotic pathway, and by arresting the cell cycle at Gi/S phase. 
Berberine induces apoptotic events in HCC cell lines through procaspase-9, and its 
effector caspases, procaspase-3, and procaspase-7, which were involved in 
berberine-induced apoptosis. Caspase activation caused a decrease in the protein 
expression of full-length Bid in cytosol, where full-length Bid was likely to be 
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truncated and translocated to mitochondria, which consequentially resulted in 
apoptotic death. Our findings show that berberine possesses potent anti-cancer 
activities in human hepatocellular carcinoma. 
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